Alzheimer’s researchers and curious readers: discover a lively take on a company’s evolving case for multi-target approaches and cross-disease implications.
Key Takeaways
- PrimeC combines two FDA-approved drugs into a single extended-release oral therapy
- RoAD proof-of-concept trial randomized eight Alzheimer’s participants to PrimeC or placebo
- Biomarker shifts resembled earlier ALS data, suggesting shared neurodegenerative biology engagement